|
|
BY OUR PHARMA CORRESPONDENT
22 July, 2005: The Mumbai-based pharmaceutical firm Lupin Ltd has launched the generic version of new generation antibiotic ceftriaxone vials for injection in the US market.
Lupin’s ceftriaxone is the generic equivalent of Rocephin marketed by Roche. As per MAT May 2005 IMS data, the US market size for ceftriaxone was at $ 756 million.
This cephalosporin antibiotic injection is used to treat infections of the urinary tract, lower respiratory tract, meningitis, skin and skin structure, surgical prophylaxis, intra-abdominal infections and pelvic inflammatory disease, a company release said.
The launch of ceftriaxone significantly enhances Lupin’s presence in the US generic market, stated Dr Desh Bandhu Gupta, Chairman, Lupin Ltd, in the release
Earlier in October 2003, Lupin had received the ANDA approval from the US FDA for 250 mg, 500 mg, 1g and 2g variants of ceftriaxone vials for injection. The launch follows the expiry of the product patent on July 19, 2005.
Baxter Healthcare Corporation, a leading global medical products company headquartered in the United States with whom the company has entered into an agreement will exclusively distribute the company’s ceftriaxone vials in the US hospital market. Lupin has also entered into a separate agreement with Henry Schein, Inc. for the sale of this product to physician offices, the release said.
|
